trict adherence to pharmacological dosage regimens is a prerequisite to the success of most treatments, particularly for patients in drug abuse programs or in patients with chronic pain who are on opioids for pain control. Although urine drug screening collection procedures attempt to ensure specimen integrity, some patients demonstrate considerable ingenuity in their efforts to defeat the testing process. [1] [2] [3] [4] S Possible methods of avoiding drug misuse detection include diversion, excessive water consumption, ingesting diuretics such as herbal teas, and substitution of someone else's urine.
Individuals who divert pain medication for illegitimate resale often "hold" a few pills to be taken before a physician visit. This allows the medication to appear in their urine ensuring that the physician will extend the prescription, thereby allowing continued diversion of the medication.
Individuals also overuse medications, often gaining it from multiple sources. These individuals pass basic presence/absence screening tests and continue to receive the medication. A recent retrospective study with a chronic pain population using urine screen monitoring suggested that 75% of patients were likely not taking their pain medication as prescribed. 5 While laboratory assays are quantitative, current screening tests can only assure presence or absence of drug metabolites in the urine. The major problem facing urine testing is the large amount of variance in urine drug concentrations, mostly due to variations in hydration and urinary output volume. In a recent study by the Clinical Pharmacology and Therapeutics Research Branch of the National Institute on Drug Abuse, this variability proved to be too great to permit estimation of methadone dose or missed doses; however, another group of researchers did report clear benefit from the use of urine creatinine to adjust for urine methadone and EDDP doi:10.3121/cmr.2009.859 concentrations using a semiquantitative immunoassay, and did find that these values were lower on days after missed doses. 6 Currently, no quantitative screening method is available that accurately identifies individuals who are non-compliant with the prescribed dosage regimen through over-or under-use. Such a method would be of tremendous clinical benefit if it could be developed to allow statistical analysis of a single sample, thereby allowing a prescribing provider the ability to understand use of the medication as prescribed versus over-or under-use.
Oral creatine supplementation is widely used in athletes attempting to enhance their performance.
This should not interfere with the proposed monitoring method. Several studies have demonstrated that neither short-term, medium-term, nor long-term oral creatine supplements have any significant effects on urine excretion rates for creatinine, urea, and albumin in healthy individuals. 7, 8 Of more concern is the fact that intra-individual variability in renal excretion of creatinine can be temporarily increased by meat consumption. [9] [10] [11] This variability may account for 10% to 29% of between-day variation in calculated creatinine clearance for a given individual. 12 The purpose of this study was to explore the possibility of using methadone metabolite/urine creatinine ratios to develop a regression model for predicting methadone adherence over a clinically significant range of prescribed dosages in patients on methadone therapy for chronic pain or opioid addiction. Methadone is prescribed under strict dosage regimens to patients in substance abuse programs, is closely monitored in chronic pain patients, and has a readily quantifiable urinary metabolite (EDDP; 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine). The direct methadone metabolite (methadone) was not assessed during this study, as it was not reported in these samples by our system's laboratory. Marshfield Clinic Laboratory only began 
Urine Collection
On a weekly basis, reasonably random urine screens were required of all methadone maintenance patients to assess for drugs of abuse. Chronic pain patients all signed an opioid agreement requiring random urine screens for levels of (1) the prescribed drug, (2) other opioid medications, and (3) street or illicit drugs. No specific collection times, based on methadone dosing, were defined. This was not believed to affect metabolite detection outcomes. In future studies, urine collection times will be specified to eliminate this potential variable.
Urine was collected following the standard protocol for urine toxicity screening, such as for methadone and its metabolite EDDP. Other drugs were identified, but their impact on this study
were not analyzed. Clinic drug abuse or chronic pain patients were provided 30 mL specimen cups with temperature-sensitive strips (Lynn Peavey Co., Lenexa, KS). If urine temperature was appropriate for a "fresh" urine specimen (90-100F per temperature strips), it was transferred to doi:10.3121/cmr.2009.859
the laboratory for determination of urine creatinine level and a drug of abuse test that included EDDP quantitation via gas chromatography/mass spectrometry analysis.
Creatinine Determinations
Creatinine levels were determined employing the Jaffe reaction (DRI ® Creatinine-Detect, Microgenics Corp., Fremont, CA), whereby a red creatinine-picrate complex is formed. 13 The rate of formation of the color product was measured using bichromatic pairing (absorbance at 505 nm minus nonspecific absorbance at 570 nm). Samples were colorimetrically analyzed on a
Hitachi 717 analyzer (Hitachi Chemical Diagnostics, Inc., Mountain View, CA). The reaction rate was used to construct a linear standard curve from which the concentration of creatinine was calculated.
EDDP Determinations
Aliquots of the urine specimens were first screened for drugs of abuse by routine immunoassay.
Each presumptive positive specimen was subjected to confirmatory testing. In the case of methadone, EDDP was quantitatively measured by gas chromatography/mass spectrometry (GC/MS) with selected ion monitoring, following the method of Baugh et al 14 EDDP and D3-EDDP, but not EMDP, were monitored to determine methadone in the urine samples. The internal standard made a small contribution to the analyte ion chromatograms, especially to the 262 ion. This limited the sensitivity of the assay to a limit of detection of ~10 ng/mL. All samples were above the limit of detection and were appropriately quantified.
Urine Creatinine Correction
EDDP/creatinine ratios were calculated by dividing the EDDP level (ng/mL) by the urine creatinine level (mg/dL).
Body Size
Body surface areas (BSA) were calculated according to the Mosteller formula: models were used to ensure that the final models adequately represented the observed data.
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Observations judged "non-compliant" were not included in the development of the models, but are included in plots to illustrate deviations from valid results predicted by the models. The predictive ability of the final model is illustrated with sensitivity (% of non-compliant observations correctly identified) and specificity (% of compliant observations correctly identified), where this classification is based on the studentized (i.e. normalized) residuals from the model. These studentized residuals (r s ) might be used, as with other clinical Z-scores, to flag unusual values, in this case as potentially reflecting non-compliance. Results in this report were deemed statistically significant at the 5% level (P<0.05). Other substance metabolites (e.g., oxycodone, morphine) may have been present in the urine screens; however, for the purpose of this retrospective study, they were not included in this data set and were not analyzed in any way. Table 1 describes the patients and their urine screening observations. The seven patients in group 1 ranged in age from 25 to 51 years, and 3 (43%) were male. The 33 patients in group 2 ranged in age from 20 to 56, and 21 (64%) were male. Of the 40 total patients, 3 were receiving methadone therapy for substance abuse, with the remaining 37 receiving the therapy for chronic pain management. All patients were considered to have achieved "steady state" and were taking medication on a consistent dosing schedule at the time of the assessments; the only exceptions were when non-compliance with the prescribed dosing regimen had been documented. Figure 1A indicates a significant positive relation (P<0.001) of the valid EDDP results by dose from group 1. However, there was also substantial variability (R adj 2 =0.49). As shown in figure 1B , adjustment for creatinine using EDDP/creatinine ratios provided a much tighter relation (R adj 2 =0.95). Figure 1C illustrates 
Results

Patient Characteristics
Predictive Modeling -Group 1
Predictive Modeling -Group 2
In order to validate the results above, the analyses were repeated in a larger, independent group of patients. The valid EDDP results by dose for group 2 are shown in figure 2A . Once again, there was a significant positive relation (P<0.001) but also substantial variability (R adj 2 =0.53). As in the original group of patients, adjustment for creatinine through the EDDP/creatinine ratio provided a substantially stronger relation (R adj 2 =0.73, figure 2B ). The fit of the same model by plotting EDDP/creatinine as predicted by the model versus the observed value for group 2 is shown in figure 2C and includes the identity line representing perfect prediction by the model. A plot of EDDP/creatinine ratios predicted by the model versus the observed EDDP/creatinine values again indicates considerable deviation for confirmed non-compliant dosing ( figure 2C ).
Predictive Modeling -Combined Groups
In additional analyses, all patients were combined in order to consider whether patient characteristics may also relate to the EDDP/creatinine ratio. 
Discussion
A relationship between urinary EDDP/creatinine ratios was found to predict the consumed dosage of methadone across the clinically significant range used in drug abuse and chronic pain patients. This confirms the previous results using EDDP with creatinine correction and further was able to confirm non-compliance in the form of over-or under-use 6 . Correction for creatinine removed a substantial proportion of the variability associated with urine testing results. better information about how their patient is using the prescribed medication, leading to better clinical decision-making. Future research may also look at the additional benefit of utilizing EDDP along with methadone level to improve confidence intervals and the ability to identify appropriate versus inappropriate therapy use.
It is important for clinicians to be aware of any patient's inappropriate use of prescribed, overthe-counter, and/or illicit drugs to properly manage care. Although use of external sources of information may be helpful (such as interviews with spouses, review of medical records, or input from prescription monitoring programs), testing of biological samples, especially urine, has the greatest potential for monitoring true compliance. 19 Hawks 20 first suggested using creatinine normalization to correct for variations in metabolite urine tests. Creatinine is a metabolite of creatine and is an end-product of muscle metabolism excreted in the urine. Creatinine formation and excretion are directly proportional to total muscle mass and roughly proportional to body weight. Creatinine is excreted in relatively constant amounts of 1.0 to 2.5 g/day regardless of urinary volume, 9,10 and normalization of the excretion of a drug to the creatinine concentration may reduce the variability of analyte measurement attributed to urine dilution. Total 24-hour creatinine determinations have been utilized for checks on 24-hour urine collection adherence. Also, in forensic science, drug metabolite to creatinine ratios is utilized for reducing false negative results caused by urine specimen dilution. Creatinine ratios have not, however, been applied to assessments of whether patients are adhering to prescribed drug treatment regimens.
Normalizing urine drug concentrations to urine creatinine values has been attempted for drugs such as marijuana, [21] [22] [23] [24] amphetamine, 25 cocaine, 26 nicotine, 27 and buprenorphine. 28 Most of these applications, however, have been designed with the specific aim of avoiding false negative results in drug screening programs due to very dilute urine specimens. 22 on normalization of cocaine urine testing results to urine creatinine. Quantitative benzoylecgonine (BE) to urine creatinine levels allowed for the differentiation of positive BE levels arising from washout and from positive BE levels resulting from new cocaine use. 26 Preston et al 6 reported the benefit of this method for correcting to creatinine, for methadone and its main metabolite EDDP, when they are determined by semiquantitative CEDIA DAU immunoassays. Our study suggests that the same approach may be useful in monitoring methadone adherence in clinically relevant situations using GC/MS. These parameters were not considered in this study, but may be worthy of consideration in future studies as they have been found to provide interpretative benefit. 5 We present our predictive model for illustration, and realize it will require further development and validation prior to any clinical application.
Conclusion
Our data were sufficient to yield a highly significant regression that permitted the demonstration If further validation of this model is achieved, potentially with new factors that would allow even tighter confidence intervals, not only for methadone, but also for other opioid medications (e.g.,oxycodone or morphine products) or psychostimulant medications, many of which are abused, misused or diverted, a dramatic improvement in a physicians ability to manage medications appropriately could be attained. This could lead to physicians identifying medication diverters or abusers more quickly, thus leading to a dramatic reduction in risk to patients, abusers or the community. The current urine screen model, which is clearly inadequate, would be much improved and the overall decision-making by physicians in the context of medication could be substantially advanced. Methadone adherence testing via urine screens Page 27 Figure 3 . Variability of the line of identity (log scale) in the model decreases when EDDP/creatinine ratios are adjusted for LBW, using combined data from group 1 and 2 (▲= non-compliant dosing, ∆ = methadone daily doses).
